Navigation Links
CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
Date:8/3/2010

GREENWOOD VILLAGE, Colo., Aug. 3 /PRNewswire-FirstCall/ -- Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE), discovered an error in the title of its press release on July 27, and provides the corrected title to that release above. As reflected in the body of the press release, Ampio has completed the final negotiations with DMI BioSciences, Inc. concerning the pending acquisition of DMI BioSciences. Ampio will file a Form 8-K with the SEC announcing the definitive agreement upon its execution.  

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation and CNS disease. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near-term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs.

About DMI BioSciences, Inc.

DMI BioSciences, Inc. was founded by Dr. David Bar-Or in 1990 to develop innovative diagnostic tests and drugs for the medical device and biopharmaceutical industry. 

Safe Harbor Statement

Certain of the above statements contained in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those indicated in the forward-looking statements as a result of various factors.

Investor Contact: Redwood Consultants, LLC Tel: +1 415-884-0348


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
2. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
3. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
4. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
5. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
6. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
7. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
8. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
9. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
10. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
11. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... In a list published by the Boston ... 76 fastest-growing private companies; a small percentage of the state's 615,000+ small businesses. The ... percent change in revenue from 2012 to 2015. , As this award ...
(Date:5/3/2016)... CO (PRWEB) , ... May 03, 2016 , ... ... , announced the addition of Dr. Nancy Gillett to its Board of Directors. ... position, she served as Corporate Executive Vice President and Chief Scientific Officer. A ...
(Date:5/3/2016)... York, NY (PRWEB) , ... May 03, 2016 ... ... and NeuroTech NYC , the sensor and data driven conferences, will take place ... UnitedHealth's Vidya Raman-Tangella on incorporating technology -- including AR/VR, ...
(Date:5/3/2016)... May 3, 2016  Dr. Thomas P. McHugh ... The Woodlands, Texas , now offers ... of treated fat cells in just 25-minutes, leaving a ... 90 percent of Americans report feeling bothered by excess ... reduction procedures are a growing industry. This innovative new ...
Breaking Biology Technology:
(Date:3/11/2016)... PUNE, India , March 11, 2016 ... to a new market research report "Image Recognition Market ... by Application (Marketing and Advertising), by Deployment Type (On-Premises ... Global Forecast To 2022", published by MarketsandMarkets, the global ... in 2015 to USD 29.98 Billion by 2020, at ...
(Date:3/9/2016)... PALM BEACH GARDENS, Fla. , March 9, ... of identity management authentication and enrollment solutions, today ... proven DigitalPersona ® Altus multi-factor ... enable IT and InfoSec managers to step-up security ... friction.  Washington, DC ...
(Date:3/2/2016)... March 2, 2016 ... addition of the  "Global Biometrics Market in ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , Global biometrics ... at a CAGR of around 27%   ... has announced the addition of the  "Global ...
Breaking Biology News(10 mins):